CA3079374A1 - Treatment of cd20-positive b-cell lymphoma with obituzumab - Google Patents
Treatment of cd20-positive b-cell lymphoma with obituzumab Download PDFInfo
- Publication number
- CA3079374A1 CA3079374A1 CA3079374A CA3079374A CA3079374A1 CA 3079374 A1 CA3079374 A1 CA 3079374A1 CA 3079374 A CA3079374 A CA 3079374A CA 3079374 A CA3079374 A CA 3079374A CA 3079374 A1 CA3079374 A1 CA 3079374A1
- Authority
- CA
- Canada
- Prior art keywords
- obinutuzumab
- hour
- cycle
- administration
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574297P | 2017-10-19 | 2017-10-19 | |
| US62/574,297 | 2017-10-19 | ||
| PCT/JP2018/038924 WO2019017499A2 (en) | 2017-10-19 | 2018-10-19 | PHARMACEUTICAL COMPOSITION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3079374A1 true CA3079374A1 (en) | 2019-01-24 |
Family
ID=64362606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3079374A Pending CA3079374A1 (en) | 2017-10-19 | 2018-10-19 | Treatment of cd20-positive b-cell lymphoma with obituzumab |
Country Status (14)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3697818T3 (pl) * | 2017-10-19 | 2025-03-24 | F. Hoffmann-La Roche Ag | Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem |
| AU2020356896B2 (en) * | 2019-10-04 | 2026-07-30 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of cell proliferation in obinutuzumab resistant CD20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type II anti-CD20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto |
| WO2023042679A1 (ja) | 2021-09-17 | 2023-03-23 | キヤノン株式会社 | 送電装置および受電装置 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| WO2009080541A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Antibody formulation |
| RS63364B1 (sr) | 2014-08-11 | 2022-07-29 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora |
| US11149091B2 (en) * | 2015-12-09 | 2021-10-19 | Cedars-Sinai Medical Center | Methods for treating nephrotic syndrome |
| CN108395482B (zh) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| US12377681B2 (en) | 2017-07-21 | 2025-08-05 | The Yokohama Rubber Co., Ltd. | Pneumatic tire |
| PL3697818T3 (pl) * | 2017-10-19 | 2025-03-24 | F. Hoffmann-La Roche Ag | Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem |
-
2018
- 2018-10-19 PL PL18804720.3T patent/PL3697818T3/pl unknown
- 2018-10-19 ES ES18804720T patent/ES3005784T3/es active Active
- 2018-10-19 BR BR112020007731-3A patent/BR112020007731A2/pt unknown
- 2018-10-19 IL IL273909A patent/IL273909B2/en unknown
- 2018-10-19 TW TW112120572A patent/TWI828593B/zh active
- 2018-10-19 WO PCT/JP2018/038924 patent/WO2019017499A2/en not_active Ceased
- 2018-10-19 MX MX2020003418A patent/MX419643B/es unknown
- 2018-10-19 EP EP18804720.3A patent/EP3697818B1/en active Active
- 2018-10-19 CN CN201880067120.XA patent/CN111212854A/zh not_active Withdrawn
- 2018-10-19 CN CN202511095071.9A patent/CN120983618A/zh active Pending
- 2018-10-19 AU AU2018303836A patent/AU2018303836B2/en active Active
- 2018-10-19 CA CA3079374A patent/CA3079374A1/en active Pending
- 2018-10-19 JP JP2019508989A patent/JP6860652B2/ja active Active
- 2018-10-19 KR KR1020257043253A patent/KR20260011191A/ko active Pending
- 2018-10-19 KR KR1020207014191A patent/KR102766089B1/ko active Active
- 2018-10-19 US US16/756,057 patent/US12129304B2/en active Active
- 2018-10-19 TW TW107137033A patent/TWI805630B/zh active
- 2018-10-19 EP EP24213649.7A patent/EP4520347A3/en active Pending
- 2018-10-19 IL IL321935A patent/IL321935A/en unknown
- 2018-10-19 KR KR1020247035575A patent/KR102906969B1/ko active Active
-
2020
- 2020-07-13 MX MX2024009217A patent/MX2024009217A/es unknown
-
2021
- 2021-03-26 JP JP2021052571A patent/JP7370357B2/ja active Active
-
2024
- 2024-09-23 US US18/893,101 patent/US20250026847A1/en active Pending
-
2025
- 2025-07-15 AU AU2025205481A patent/AU2025205481A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273937B2 (en) | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof | |
| US20250026847A1 (en) | Treatment of cd20-positive b-cell lymphoma with obinutuzumab | |
| US20250074979A1 (en) | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| US20230014026A1 (en) | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint | |
| TW202126689A (zh) | 抑制具奧比妥珠單株抗體耐受性的cd20陽性癌之細胞增殖的藥劑，及其相關之醫藥組成物、醫藥、製造、抑制細胞增殖的方法、治療方法、ii型抗cd20抗體、化合物及其組合、增強劑以及誘導劑 | |
| HK40031517A (en) | Treatment of cd20-positive b-cell lymphoma with obituzumab | |
| TW202402791A (zh) | 抗ｉｌ－２７抗體之用途 | |
| CZ20032672A3 (cs) | CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy | |
| BR122025025322A2 (pt) | Composição farmacêutica para o tratamento de linfoma de células b e uso do obinutuzumabe | |
| US12599620B2 (en) | Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells | |
| EA051578B1 (ru) | Терапия анти-cd19 в комбинации с леналидомидом для лечения лейкоза или лимфомы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230922 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240923 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240923 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240923 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240926 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED Effective date: 20250121 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250325 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250403 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250716 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250716 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: N-6-6-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250902 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250911 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250925 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250925 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260330 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260728 |